linjc16/ctgov huggingface dataset:
Regional Hemodynamic Parameter Changes After Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
Spinal anesthesia is a regional anesthesia method used for surgical procedures generally involving the lower abdominal area, perineum, and lower extremities. Various tests are performed to evaluate the block level after spinal anesthesia, incluyding pinprick test, cold application, and motor examination. These tests are performed to check whether the pain, sympathetic and motor nerve fibers are affected, respectively, after the block; and good communication with the patient is important here. However, it is extremely difficult to evaluate these tests in pediatric, geriatric, mentally retarded or uncooperative patients. Sympathectomy can be used as a criterion to evaluate the success of the block that occurs after the spinal anesthesia procedure. Sympathetic nerve fibers are the first to be affected by the block, and the success of the block can be evaluated with the revealed sympathectomy. Sympathectomy in the lower extremities after spinal block increases arterial blood flow. This increase in blood flow can be detected by the Pulsed Wave Doppler feature of USG.

Official Title
-----------------
Measurement of Regional Hemodynamic Parameters Before and After Spinal Anesthesia With Doppler USG

Conditions
-----------------
Spinal Anesthesia Evaluation

Intervention / Treatment
-----------------
* Diagnostic Test: Pulsed Wave Doppler USG examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective surgery under spinal anesthesia American Society of Anesthesiologists (ASA) I-II physical status Exclusion Criteria: Contraindication for spinal anesthesia ASA physical status >II Vasoactive drug usage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial velocity changes | Posterior tibial artery velocities (peak systolic, end-diastolic) and vessel diameters will be measured after the spinal anesthesia procedure. | At the 5th and 10th minutes after the spinal anesthesia procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal anesthesia, Test, Pulsed Wave Doppler, Sympathectomy
Vascular Physician Offer and Report (VAPOR) Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to see if vascular physicians (your provider) using a combination of proven smoking cessation tools in an organized way can help vascular patients quit smoking better than usual. The doctors where you are being treated have been chosen to either provide: the combination therapy of giving you advice, considering prescribing medications to help you quit smoking, and referring you to a phone quitline, or to continue their usual smoking cessation practices (which may include all, some, or none of the treatments above).

Official Title
-----------------
Vascular Physician Offer and Report (VAPOR) Trial

Conditions
-----------------
Peripheral Artery Disease (PAD)

Intervention / Treatment
-----------------
* Behavioral: Offer and Report Protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 Current smoker Plan to have a Vascular Quality Initiative (VQI) procedure in > 7 days Exclusion Criteria: Pregnant Women, Fetuses and Neonates Children People with impaired decision-making capacity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Offer and Report Protocol<br>Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy. | Behavioral: Offer and Report Protocol<br>* Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.<br>|
| No Intervention: Usual Care<br>Physician will follow their institution's standard of care for smoking cessation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of the Offer and Report protocol for change in smoking status from Baseline Visit to 3 Month Visit | To assess the efficacy of the Offer and Report protocol (standardized (1) very brief advice, (2) referral to telephone-based smoking cessation counseling, and (3) consideration of prescribing nicotine replacement therapy (NRT)) as compared to usual smoking cessation care by vascular physicians in biochemically-validated 3 month smoking cessation rates. A questionnaire will be completed by the patient at the Baseline visit and another questionnaire will be completed at the 3 month visit to assess the change in smoking status. | Change in smoking status from Baseline Visit to 3 Month Visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PAD, VAPOR, smoking cessation
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Study Overview
=================
Brief Summary
-----------------
The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.

Official Title
-----------------
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Conditions
-----------------
Respiratory Disorders

Intervention / Treatment
-----------------
* Drug: Salmeterol and Fluticasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must use fluticasone and salmeterol for the first time Exclusion Criteria: Patients with hypersensitivity to salmeterol and fluticasone Patients with infection which salmeterol and fluticasone is not effective Patients with deep mycosis
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients prescribed fluticasone and salmeterol<br>Patients with asthma prescribed fluticasone and salmeterol during study period | Drug: Salmeterol and Fluticasone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate |  | 6 months |
Acupuncture Treatment of Dry Eye

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and efficacy of acupuncture in the treatment of moderate to severe dry eye by replicating the study design of the previous protocol and to see the study through to its completion.

Official Title
-----------------
Acupuncture Treatment of Dry Eye

Conditions
-----------------
Keratoconjunctivitis Sicca, Xeropthalmia

Intervention / Treatment
-----------------
* Procedure: Acupuncture
* Procedure: Sham acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Military healthcare beneficiary Male and female patients, at least 18 years of age Diagnosis of keratoconjunctivitis sicca or xerophthalmia (dry eyes) in one or both eyes Persistent signs and symptoms despite conventional therapy for at least three months Exclusion Criteria: Contact lens wear Intraocular surgery or laser in the study eye within 90 days prior to enrolling in the study History of any medical condition or circumstance that would preclude scheduled visits or completion of the study Known history of adverse reaction to acupuncture Pregnancy or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Acupuncture | Procedure: Acupuncture<br>* Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.<br>|
| Sham Comparator: 2<br>Sham Acupuncture | Procedure: Sham acupuncture<br>* Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To answer the question of whether there are objective beneficial effects of an acupuncture treatment versus sham acupuncture on dry eye, as measured by some of the most widely-used clinical indicators in the literature. |  | 6 months after acupuncture or sham acupuncture treatment |
Evaluation of Position-induced Cyclorotation Between Wavefront Measurement and Refractive Surgery by the Iris Registration Method

Study Overview
=================
Brief Summary
-----------------
Cyclorotation of eyes may be affected by motion and orientation of the head and body. An automated alignment method with the technique of iris recognition was used to assess the amount and orientation of position-induced cyclorotation between preoperative wavefront measurement and laser refractive surgery.

Detailed Description
-----------------
Ninety-three consecutive patients undergoing bilateral wavefront-guided laser refractive surgery in the Department of Ophthalmology of the National Taiwan University Hospital between September 2004 and December 2007 were enrolled in this retrospective study. Before laser refractive surgery, all patients were seated in front of the Zyoptix 100 system platform (Bausch & Lomb, salt lake city, UT, USA) and received Zywave aberrometer measurement on both eyes. When patients were in the supine position for refractive surgery, an infrared camera mounted on the laser system (Technolas 217z100 excimer laser system, Bausch & Lomb)obtained iris images on undilated pupils before laser ablation. Overall cyclorotation was detected by a comparison between iris images of undilated pupils in the supine position and dilated pupils in the seated position before laser treatment. The degree and direction of position-induced cyclorotation were assessed.

Official Title
-----------------
Evaluation of Position-induced Cyclorotation Between Wavefront Measurement and Refractive Surgery by the Iris Registration Method

Conditions
-----------------
Eye Cyclorotation Degree, Pupil Shift

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing bilateral wavefront-guided laser refractive surgery Exclusion Criteria: patients with strabismus, extraocular muscle palsy, muscle restriction or other diseases interfering normal ocular movement.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cyclorotation, pupil, laser refractive surgery
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Study Overview
=================
Brief Summary
-----------------
Not significantly increased survival in T/T

Official Title
-----------------
Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chemotherapy

Conditions
-----------------
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?

Intervention / Treatment
-----------------
* Drug: Gefitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: NSCLC with spinal metastasis Exclusion Criteria: brain metastasis and expected survival < 3 months
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| targeted therapy<br>according to national healthy policy, targeted therapy is the optional therapy | Drug: Gefitinib<br> <br> * Other names: Targeted therapy;|
| traditional chemotherapy<br>according to national healthy policy, chemotherapy is the first line treatment. | Drug: Gefitinib<br> <br> * Other names: Targeted therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival and neurologic outcome of 60 participants receiving targeted therapy for nonsmall cell lung cancer with spinal metastaasis. Neurological outcome by Frankel grading and ambulation status. |  | postoperation to mortality, up to 2 year |
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

Study Overview
=================
Brief Summary
-----------------
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Detailed Description
-----------------
Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Official Title
-----------------
Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: eletriptan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-45 healthy menstruating female Exclusion Criteria: cardiac or other conditions precluding use of eletriptan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Mean Headache Index Score Among Patients | Headache index is an average headache severity score recorded using a 0-10 severity scale recorded 4 times daily. Scores are averaged to produce an average severity score which can range between 0 (no headaches) to 10 (always a maximum severity headache). Change in headache activity was evaluated by comparing mean severity scores during the 3 months pre-intervention are compared with 3 months of preventive therapy | baseline to approximately three months |
Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2

Study Overview
=================
Brief Summary
-----------------
Vitamin D Supplement in patients with CKD stage 1 and 2 may change osteoprotegin expression so as to produce beneficial effects of cardiovascular、bone metabolism and CKD progression.

Conditions
-----------------
Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2

Intervention / Treatment
-----------------
* Drug: Calcitriol
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of CKD stage 1 and 2 Age >18 years Ability to provide informed consent Exclusion Criteria: On vitamin D in past 4 weeks Plans to relocate out of Taixing City in the next one year Serum phosphate >5.5 mg/dl in past 3 months Serum calcium >10.0 mg/dl in past 3 months Cancer Transplanted organ Rapidly deteriorating kidney function with the expectation for initiation of dialysis in less than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo<br> | Drug: placebo<br>* one pill per day<br>|
| Experimental: Calcitriol<br> | Drug: Calcitriol<br>* 0.25 ug per day for one year<br>* Other names: Rocaltrol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Osteoprotegin level | To assess the effect of vitamin D supplementation on osteoprotegin level in CKD patients | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone mineral density | To assess the effect of vitamin D supplementation on bone mineral density in patients with CKD stage 1 and 2 | one year | 
| vascular calcification score | To assess the effect of vitamin D supplementation on vascular calcification score through performing lateral abdominal radiography or CT-based techniques in patients with CKD stage 1 and 2 | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcitrol, Bone mineral density, Osteoprotegin, Vascular calcification
Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)

Study Overview
=================
Brief Summary
-----------------
Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness. Treatment: corticosteroid therapy, which is effective in the vast majority of cases. Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences: Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity. Requires additional immunosuppressive treatment.

Official Title
-----------------
Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated at Nîmes Carémeau University Hospital, for Giant Cells ARTEitis (Horton's Disease), for Diagnosis and During Long-term Follow-up

Conditions
-----------------
Giant Cell Arteritis, Horton Disease

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 45 years or older Patients with giant cell arteritis according to ACR criteria or revised criteria incorporating imaging parameters, Patients managed at the University Hospital of Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical and paraclinical characteristics of patients diagnosed with ACG | Describe the clinical and paraclinical characteristics of patients diagnosed with ACG to determine whether certain characteristics are significantly associated with a higher risk of developing corticosteroid dependence | day 1 |